Novel HIV Drug Offers Hope

by Rajashri on  August 1, 2008 at 2:49 PM AIDS/HIV News
RSS Email Print This Page Comment
Font : A-A+

 Novel HIV Drug Offers Hope
A drug to treat HIV infection offers new hope for millions of patients, according to cientists at the University of New South Wales (UNSW).

The researchers say the majority of patients who have not responded to traditional treatments have had good results from a new combination therapy involving raltegravir.

They say that clinical trials have shown that raltegravir - already available in Australia - is safe and effective and has minimal side-effects when used with other anti-HIV medicines.

Writing about their observations in the New England Journal of Medicine, the researchers have revealed that raltegravir lowers the amount of virus in the blood to undetectable levels in 62 per cent of people taking it in combination with other anti-HIV medicines.

Only one in three people who received a placebo plus other anti-HIV medicines had the amount of virus in the blood reduced to similar levels, they say.

"This is the first drug in a new class of antiretroviral drugs called integrase inhibitors. The drug has a different mechanism of action, is very potent, seems very safe and has helped patients who have a virus that is resistant to older drugs and classes," says Professor David Cooper AO, the Director of UNSW's National Centre in HIV Epidemiology and Clinical Research (NCHECR).

"It initially will be used in developed countries, but hopefully it will be made available at cheaper prices for patients in developing countries who are facing the same problems," Professor Cooper adds.

The results were based on analyses of viral load reductions and increases in CD4 cell count, which is crucial for a healthy immune system.

The overall results have been drawn from two major ongoing clinical trials in Europe, Asia, Australia and North and South America.

Both studies are supported by Merck and Co, Inc., the manufacturer of raltegravir.

Source: ANI
RAS/M

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Oral Health And AIDS Drug Toxicity AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive